Amgen Posts Higher-Than-Expected Third-Quarter Results; Shares Dip
Amgen reported higher-than-expected third-quarter results and rising adjusted EPS, while its shares dipped.
Story updates
09:59:28 PM UTC
SquawkNews
By Deena BeasleyAmgen NASDAQ:AMGN on Tuesday said third-quarter sales rose 8%, led by cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy Uplizna, as the company moves ahead with development of its high-profile experimental weight-loss drug MariTide.But s…
10:00:01 PM UTC
SquawkNews
UPDATE 1-アムジェン、第3四半期の業績は予想を上回ったものの、株価は下落した 調整後ＥＰＳは１４％増の６．４５ドルに ２６年のＥＰＳ見通しは、売上高３８９億～３９７億ドルを前提に、２２．９０～
10:02:35 PM UTC
SquawkNews
종합 1-암젠, 3분기 실적은 예상보다 좋았으나 주가는 하락 조정 주당순이익(EPS)이 14% 상승한 6.45달러를 기록 2026년 EPS 전망치를 22.90달러에서 23.70달러